Hyperphosphataemia — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Increase Sevelamer dose to 1600 mg TDS
The patient has hyperphosphataemia despite current binder therapy and dietary counselling. The first step is to optimise the current binder dose. Sevelamer can be increased to 1600 mg TDS (or even higher). Adding or switching to a calcium-based binder is less appropriate given the patient's calcium is already in the upper normal range. KDIGO CKD-MBD 2017 update suggests restricting calcium-based binders in this context. Lanthanum is an option if Sevelamer is maximised.
Reference: KDIGO 2017 – CKD-MBD Guideline Update